Clinical application of antibody microarray in chronic kidney disease: How far to go?

Proteomics - Clinical Applications

Volumn 2, Issue 7-8, 2008, Pages 989-996

  Lv, Lin Li ^a   Liu, Bi Cheng ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Antibody microarray; Chronic kidney disease; Disease biomarker; Renal fibrosis

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ALPHA 1 MICROGLOBULIN; ANGIOTENSIN II; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; CREATINE; ENDOTHELIN; FATTY ACID BINDING PROTEIN; FIBRINOGEN; INTERLEUKIN 10; MATRIX METALLOPROTEINASE; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SCLEROPROTEIN; TAMM HORSFALL GLYCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANTIBODY MICROARRAY; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY TUBULE FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN MICROARRAY; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; PROTEINURIA; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 50849110183     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780134     Document Type: Review

References (75)

1. Couser, W. G., Shah, S., Kopple, J., Beerkens, P. et al., A call to action on World Kidney Day, 8 March 2007. Kidney Int. 2007, 71, 369-370.
2. Schnaper, H. W., Kopp, J. B., Why kidneys fail: Report from an American Society of Nephrology Advances in Research Conference. J. Am. Soc. Nephrol. 2006, 17, 1777-1781.
3. Lv, L. L., Liu, B. C., High-throughput antibody microarrays for quantitative proteomic analysis. Expert Rev. Proteomics 2007, 4, 505-513.
4. Strutz, F., Zeisberg, M., Renal fibroblasts and myofibroblasts in chronic kidney disease. J. Am. Soc. Nephrol. 2006, 17, 2992-2998.
5. Liu, Y., Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int. 2006, 69, 213-217.
6. Li, M. X., Liu, B. C., Epithelial to mesenchymal transition in the progression of tubulointerstitial fibrosis. Chin. Med. J. 2007, 120, 1925-1930.
7. El Nahas, M., Renal remodelling: Complex interactions between renal and extra-renal cells. Pediatr. Nephrol. 2006, 21, 1637-1639.
8. Liu, B.C., Xia, H. L., Wu, J. N., Zhang, X. L. et al., Influence of irbesartan an expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction. Acta Pharmacol. Sin. 2007, 28, 1810-1818.
9. Liu, B. C., Li, M. X., Zhang, J. D., Liu, X. C. et al., Inhibition of integrin-linked kinase via a siRNA expression plasmid attenuates connective tissue growth factor-induced human proximal tubular epithelial cells to mesenchymal transition. Am. J. Nephrol. 2007, 28, 143-151.
10. Huang, Y., Noble, N. A., PAI-1 as a target in kidney disease. Curr. Drug Targets 2007, 8, 1007-1015.
11. Liu, B. C., Zhang, J. D., Zhang, X. L., Wu, G. Q. et al., Role of connective tissue growth factor (CTGF) module 4 in regulating epithelial mesenchymal transition (EMT) in HK-2 cells. Clin. Chim. Acta 2006, 373, 144-150.
12. Dhaun, N., Goddard, J., Webb, D. J., The endothelin system and its antagonism in chronic kidney disease. J. Am. Soc. Nephrol. 2006, 17, 943-955.
13. Lenz, O., Elliot, S. J., Stetler-Stevenson, W. G., Matrix metalloproteinases in renal development and disease. J. Am. Soc. Nephrol. 2000, 11, 574-581.
14. Catania, J. M., Chen, G., Parrish, A. R., Role of matrix metalloproteinases in renal pathophysiologies. Am. J. Physiol. Renal Physiol. 2007, 292, F905-F911.
15. Liu, B. C., Xu, Y., Ma, K. L., Huang, H. Q. et al., Effects of irbesartan on the expression of matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 in streptozotocin-induced diabetic rat kidney. Chin. Med. J. 2005, 118, 1040-1044.
16. Mu, W., Ouyang, X., Agarwal, A., Zhang, L. et al., IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J. Am. Soc. Nephrol. 2005, 16, 3651-3660.
17. Dai, C. S., Liu, Y., Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta 1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J. Am. Soc. Nephrol. 2004, 15, 1402-1412.
18. Sugimoto, H., Grahovac, G., Zeisberg, M., Kalluri, R., Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007, 56, 1825-1833.
19. Hewitt, S. M., Dear, J., Star, R. A., Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 2004, 15, 1677-1689.
20. Perco, P., Pleban, C., Kainz, A., Lukas, A. et al., Protein biomarkers associated with acute renal failure and chronic kidney disease. Eur. J. Clin. Invest. 2006, 36, 753-763.
21. Fliser, D., Kollerits, B., Neyer, U., Ankerst, D. P. et al., Urinary Angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J. Am. Soc. Nephrol. 2007, 18, 1558-1565.
22. Descamps-Latscha, B., Witko-Sarsat, V., Nguyen-Khoa, T., Nguyen, A. T. et al., Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in non-diabetic predialysis patients. Am. J. Kidney Dis. 2005, 45, 39-47.
23. Fliser, D., Kollerits, B., Neyer, U., Ankerst, D. P. et al., Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study. J. Am. Soc. Nephrol. 2007, 18, 2600-2608.
24. Soylemezoglu, O., Wild, G., Dalley, A. J., MacNeil, S. et al., Urinary and serum type III collagen: markers of renal fibrosis. Nephrol. Dial. Transplant. 1997, 12, 1883-1889.
25. Kamijo, A., Sugaya, T., Hikawa, A., Yamanouchi, M. et al., Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J. Lab. Clin. Med. 2005. 145, 125-133.
26. Fliser, D., Novak, J., Thongboonkerd, V., Argilés, A. et al., Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol. 2007, 18, 1057-1071.
27. Pisitkun, T., Johnstone, R., Knepper, M. A., Discovery of urinary biomarkers. Mol. Cell. Proteomics 2006, 5, 1780-1771.
28. Thongboonkerd, V., Proteomics in nephrology: Current status and future directions. Am. J. Nephrol. 2004, 24, 360-378.
29. Weissinger, E. M., Kaiser, T., Meert, N., De Smet, R. et al., Proteomics: A novel tool to unravel the patho-physiology of uraemia. Nephrol. Dial. Transplant. 2004, 19, 3068-3077.
30. Haubitz, M., Wittke, S., Weissinger, E. M., Walden, M. et al., Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005, 67, 2313-2320.
31. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 15, 23-60.
32. Lv, L. L., Liu, B. C., Zhang, C. X., Tang, Z. M. et al., Construction of an antibody microarray based on agarose-coated slides. Electrophoresis 2007, 28, 406-413.
33. Borrebaeck, C. A., Antibody microarray-based oncoproteomics. Expert Opin. Biol. Ther. 2006, 6, 833-838.
34. Srivastava, M., Eidelman, O., Jozwik, C., Paweletz, C. et al., Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol. Genet. Metab. 2006,87, 303-310.
35. Shafe, M. W., Mangold, L., Partin, A. W., Haab, B. B. et al., Antibody array profiling reveals serum TSP-1as a marker to distinguish benign from malignant prostatic disease. The Prostate 2007, 67, 255-267.
36. Ekins, R., Chu, F., Biggart, E., Multispot, multianalyte, immunoassay. Ann. Biol. Clin. 1990, 48, 655-666.
37. Claus Hultschig, C., Kreutzberger, J., Seitz, H., Konthur, Z. et al., Recent advances of protein microarrays. Curr. Opin. Chem. Biol. 2006, 10, 4-10.
38. Kingsmore, S. F., Multiplexed protein measurement: Technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 2006, 5, 310-321.
39. Templin, M. F., Stoll, D., Bachmann, J., Joos, T. O., Protein microarrays and multiplexed sandwich immunoassays: What beats the beads? Comb. Chem. High Throughput Screen. 2004, 7, 223-229.
40. Espina, V., Woodhouse, E. C., Wulfkuhle, J., Asmussen, H. D. et al., Protein microarray detection strategies: Focus on direct detection technologies. J. Immunol. Methods 2004, 290, 121-133.
41. Haab, B. B., Applications of antibody array platforms. Curr Opin Biotechnol. 2006, 17, 415-421.
42. Wingren, C., Ingvarsson, J., Dexlin, L., Szul, D. et al., Design of recombinant antibody microarrays for complex proteome analysis: Choice of sample labeling-tag and solid support. Proteomics 2007, 7, 3055-3065.
43. Ingvarsson, J., Larsson, A., Sjöholm, A. G., Truedsson, L. et al., Design of recombinant antibody microarrays for serum protein profiling: Targeting of complement proteins. J. Proteome Res. 2007, 6, 3527-3536.
44. MacBeath, G., Protein microarrays and proteomics. Nat Genet. 2002, 32, 528-532.
45. Wu, T., Xie, C., Wang, H. W., Zhou, X. J. et al., Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 2007, 179, 7166-7175.
46. Locatelli, F., Vecchio, L. D., Pozzoni, P., The importance of early detection of chronic kidney disease. Nephrol. Dial. Transplant. 2002, 17, 2-7.
47. Woodhouse, S., Batten, W., Hendrick, H., Malek, P. A., The glomerular filtration rate: an important test for diagnosis, staging, and treatment of chronic kidney disease. Lab. Med. 2006, 37, 244-247.
48. New, J. P., Middleton, R. J., Klebe, B., Farmer, C. K. et al., Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet. Med. 2007, 24, 364-369.
49. Coresh, J., Astor, B. C., Greene, T., Eknoyan, G. et al., Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. Am. J. Kidney Dis. 2003, 41, 1-12.
50. Ryan, T. P., Sloand, J. A., Winters, P. C., Corsetti, J. P. et al., Chronic kidney disease prevalence and rate of diagnosis. Am. J. Med. 2007, 120, 981-986.
51. Bello, A. K., Nwankwo, E., El Nahas, A. M., Prevention of chronic kidney disease: A global challenge. Kidney Int. Suppl. 2005, 98, S11-S17.
52. Hallan, S. I., Dahl, K., Oien, C. M., Grootendorst, D. C. et al., Screening strategies for chronic kidney disease in the general population: followup of cross sectional health survey. BMJ 2006, 18, 333, 1047-1050.
53. Pätäri, A., Forsblom, C., Havana, M., Taipale, H. et al., Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003, 52, 2969-2974.
54. Forterre, S., Raila, J., Schweigert, F. J., Protein profiling of urine from dogs with renal disease using ProteinChip analysis. J. Vet. Diagn. Invest. 2004, 16, 271-277.
55. Levey, A. S., Coresh, J., Balk, E., Kausz, A. T. et al., National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann. Intern. Med. 2003, 139, 137-147.
56. Levey, A. S., Andreoli, S. P., DuBose, T., Provenzano, R. et al., Chronic kidney disease: common, harmful, and treatable - World Kidney Day 2007. Clin. J. Am. Soc. Nephrol. 2007, 2, 401-405.
57. Nguyen, T. Q., Tarnow, L., Andersen, S., Hovind, P. et al., Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006, 29, 83-88.
58. Liu, B. C., Zhang, L., Lv, L. L., Wang, Y. L. et al., Application of antibody array technology in analysis of urinary cytokine profiles in patients with chronic kidney disease. Am. J. Nephrol. 2006, 26, 483-490.
59. Xue, J. L., Ma, J. Z., Louis, T. A., Collins, A. J., Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J. Am. Soc. Nephrol. 2001, 12, 2753-2758.
60. Herzig, K. A., Purdie, D. M., Chang, W., Brown, A. M. et al., Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J. Am. Soc. Nephrol. 2001, 12, 814-821.
61. Wang, A. Y., Wang, M., Woo, J., Lam, C. W. et al., Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J. Am. Soc. Nephrol. 2004, 15, 2186-2194.
62. Goldstein, S. L., Leung, J. C., Silverstein, D. M., Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: Effect of aspirin. Clin. J. Am. Soc. Nephrol. 2006, 1, 979-986.
63. Knickerbocker, T., Chen, J. R., Thadhani, R., MacBeath, G., An integrated approach to prognosis using protein microarrays and nonparametric methods. Mol. Syst. Biol. 2007, 3, 123.
64. Nielsen, U. B., Cardone, M. H., Sinskey, A. J., MacBeath, G. et al., Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc. Natl. Acad. Sci. 2003, 100, 9330-9335.
65. Kozarova, A., Petrinac, S., Ali, A., Hudson, J. W., Array of informatics: Applications in modern research. J. Proteome Res. 2006, 5, 1051-1059.
66. Mischak, H., Apweiler, R., Banks, H. E., Conaway, M. et al., Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 2007, 1, 148-156.
67. Chan, S. M., Ermann, J., Su, L., Fathman, C. G. et al., Protein microarrays for multiplex analysis of signal transduction pathways. Nat. Med. 2004, 10, 1390-1396.
68. VanMeter, A., Signore, M., Pierobon, M., Espina, V. et al., Reverse-phase protein microarrays: Application to biomarker discovery and translational medicine. Expert Rev. Mol. Diagn. 2007, 7, 625-633.
69. Sheehan, K. M., Calvert, V. S., Kay, E. W., Lu, Y. et al., Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell. Proteomics 2005, 4, 346-355.
70. Rai, A. J., Vitzthum, F., Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Expert Rev. Proteomics 2006, 3, 409-426.
71. Master, S. R., Bierl, C., Kricka, L. J., Diagnostic challenges for multiplexed protein microarray. Drug Discov. Today. 2006, 11, 1007-1011.
72. Kricka, L. J., Master, S. H., Validation and quality control of protein microarray-based analytical methods. Mol. Biotechnol. 2008, 38, 19-31.
73. Gu, Q., Sivanandam, T. M., Haymore, J., Experimental approach for assessing the outcome accuracy of antibody microarray experiments. J. Proteome Res. 2007, 6, 4210-4217.
74. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
75. Spisak, S., Tulassay, Z., Molnar, B., Guttman, A., Protein microchips in biomedicine and biomarker discovery. Electrophoresis 2007, 28, 4261-4273.